| Issue Date | Title | Author(s) |
| 2014 | Fate modeling of mercury species and fluxes estimation in an urban river | Tong, Yindong; Zhang, Wei; Chen, Cen; Chen, Long; Wang, Wentao; Hu, Xindi; Wang, Huanhuan; Hu, Dan; Ou, Langbo; Wang, Xuejun; Wang, Qiguang |
| Jun-2024 | The management pattern and outcomes of chronic thromboembolic pulmonary hypertension: rationale and design for a Chinese real-world study | Zhang, Shuai; Li, Yishan; Yang, Yuanhua; Gong, Sugang; Yang, Zhenwen; Hong, Cheng; Cui, Xiaopei; Wan, Jun; Ji, Yingqun; Chen, Hong; Zhu, Ling; Li, Chenghong; Cheng, Zhaozhong; Zhang, Yunhui; Wang, Qiguang; Luo, Qin; Guo, Lu; Ma, Guofeng; Han, Baoshi; Liu, Zhihong; Xiong, Changming; Wang, Lan; Ji, Qiushang; Li, Fajiu; Wang, Shengfeng; Zhang, Zhu; Zhang, Yunxia; Wang, Dingyi; Gao, Qian; Huang, Qiang; Xie, Wanmu; Zhai, Zhenguo; Wang, Chen |
| 2014 | NEXN inhibits GATA4 and leads to atrial septal defects in mice and humans | Yang, Fan; Zhou, Lei; Wang, Qiguang; You, Xin; Li, Ying; Zhao, Yong; Han, Xiaonan; Chang, Zai; He, Xin; Cheng, Chunyan; Wu, Chong; Wang, Wen-Jing; Hu, Fang-Yuan; Zhao, Ting; Li, Yang; Zhao, Ming; Zheng, Gu-Yan; Dong, Jie; Fan, Chun; Yang, Juxian; Meng, Xianmin; Zhang, Youyi; Zhu, Xianyang; Xiong, Jingwei; Tian, Xiao-Li; Cao, Huiqing |
| 12-Dec-2022 | Pulmonary Artery Denervation for Pulmonary Arterial Hypertension A Sham-Controlled Randomized PADN-CFDA Trial | Zhang, Hang; Wei, Yongyue; Zhang, Caojin; Yang, Zhenwen; Kan, Jing; Gu, Heping; Fan, Fenling; Gu, Hong; Wang, Qiguang; Xie, Dujiang; Zhang, Gangcheng; Guo, Xiaomei; Yin, Yuehui; Jin, Bowen; Zhou, Hongmei; Yang, Ziyang; Wang, Zhouming; Xin, Yu; Zhang, Chen; Meng, Lili; Wang, Xiaoyu; Sun, Jingping; Zhao, Chunxia; Zhang, Juan; Yan, Xiaoyan; Chen, Feng; Yao, Cheng; Stone, Gregg W.; Chen, Shao-Liang |
| Oct-2023 | A sham-controlled randomised trial of pulmonary artery denervation for Group 1 pulmonary arterial hypertension: one-year outcomes of the PADN-CFDA trial | Kan, Jing; Zhang, Hang; Xie, Dujiang; Wei, Yongyue; Zhang, Juan; Zhang, Caojin; Yang, Zhenwen; Gu, Heping; Fan, Fenling; Gu, Hong; Wang, Qiguang; Zhang, Gangcheng; Guo, Xiaomei; Yin, Yuehui; Wang, Xiang; Jin, Bowen; Zhou, Hongmei; Yang, Ziyang; Wang, Zhouming; Xin, Yu; Zhang, Chen; Meng, Lili; Wang, Xiaoyu; Zhao, Chunxia; Yan, Xiaoyan; Chen, Feng; Yao, Cheng; Stone, Gregg W.; Chen, Shao-Liang |
| Oct-2023 | A sham-controlled randomised trial of pulmonary artery denervation for Group 1 pulmonary arterial hypertension: one-year outcomes of the PADN-CFDA trial | Kan, Jing; Zhang, Hang; Xie, Dujiang; Wei, Yongyue; Zhang, Juan; Zhang, Caojin; Yang, Zhenwen; Gu, Heping; Fan, Fenling; Gu, Hong; Wang, Qiguang; Zhang, Gangcheng; Guo, Xiaomei; Yin, Yuehui; Wang, Xiang; Jin, Bowen; Zhou, Hongmei; Yang, Ziyang; Wang, Zhouming; Xin, Yu; Zhang, Chen; Meng, Lili; Wang, Xiaoyu; Zhao, Chunxia; Yan, Xiaoyan; Chen, Feng; Yao, Cheng; Stone, Gregg W.; Chen, Shao-Liang |
| Aug-2023 | Treatment effects of pulmonary artery denervation for pulmonary arterial hypertension stratified by REVEAL risk score: Results from PADN-CFDA trial | Zhang, Juan; Kan, Jing; Wei, Yongyue; Zhang, Caojin; Yang, Zhenwen; Gu, Heping; Fan, Fenling; Gu, Hong; Wang, Qiguang; Xie, Dujiang; Zhang, Gangcheng; Guo, Xiaomei; Yin, Yuehui; Jin, Bowen; Zhou, Hongmei; Yang, Ziyang; Wang, Zhouming; Xin, Yu; Zhang, Chen; Meng, Lili; Wang, Xiaoyu; Zhao, Chunxia; Zhang, Hang; Yan, Xiaoyan; Chen, Feng; Yao, Cheng; Benza, Raymond L.; Stone, Gregg W.; Chen, Shao-Liang |
